Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Intraoperative Sentinel Node Mapping with Technitium-99 in Lung Cancer Results of CALGB 140203 Multicenter Phase II Trial

Intraoperative Sentinel Node Mapping with Technitium-99 in Lung Cancer Results of CALGB 140203... ORIGINAL ARTICLE Intraoperative Sentinel Node Mapping with Technitium-99 in Lung Cancer Results of CALGB 140203 Multicenter Phase II Trial Michael J. Liptay, MD, Thomas A. D’amico, MD, Chumy Nwogu, MD, Todd L. Demmy, MD, Xiaofei F. Wang, PhD, Lin Gu, PhD, Virginia R. Litle, MD, Scott J. Swanson, and Leslie J. Kohman, MD; for the Thoracic Surgery Subcommittee of the Cancer and Leukemia Group B n the United States, lung cancer remains the number one Introduction: Sentinel node mapping with radioactive technetium Isource of cancer-related mortality in both men and women. in non-small cell lung cancer has been shown to be feasible in Over 160,000 deaths will be attributed to lung cancer in several single institution reports. The Cancer and Leukemia Group 2008. Complete surgical resection for localized disease is the B designed a phase II trial to test a standardized method of this most viable option for sustained remission or cure. Nonethe- technique in a multi-institutional setting. If validated, the technique less the 5 year survival after complete resection of stage I could provide a more accurate and sensitive way to identify lymph tumors is only 60 to 70%. The patients who relapse after node metastases. complete resection http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Intraoperative Sentinel Node Mapping with Technitium-99 in Lung Cancer Results of CALGB 140203 Multicenter Phase II Trial

Kohman, Leslie J.
Journal of Thoracic Oncology , Volume 4 (2) – Feb 1, 2009
Download PDF
5 pages

Loading next page...
 
/lp/wolters-kluwer-health/intraoperative-sentinel-node-mapping-with-technitium-99-in-lung-cancer-Qsm1ffjyJI

References (13)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e318194a2c3
pmid
19179896
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Intraoperative Sentinel Node Mapping with Technitium-99 in Lung Cancer Results of CALGB 140203 Multicenter Phase II Trial Michael J. Liptay, MD, Thomas A. D’amico, MD, Chumy Nwogu, MD, Todd L. Demmy, MD, Xiaofei F. Wang, PhD, Lin Gu, PhD, Virginia R. Litle, MD, Scott J. Swanson, and Leslie J. Kohman, MD; for the Thoracic Surgery Subcommittee of the Cancer and Leukemia Group B n the United States, lung cancer remains the number one Introduction: Sentinel node mapping with radioactive technetium Isource of cancer-related mortality in both men and women. in non-small cell lung cancer has been shown to be feasible in Over 160,000 deaths will be attributed to lung cancer in several single institution reports. The Cancer and Leukemia Group 2008. Complete surgical resection for localized disease is the B designed a phase II trial to test a standardized method of this most viable option for sustained remission or cure. Nonethe- technique in a multi-institutional setting. If validated, the technique less the 5 year survival after complete resection of stage I could provide a more accurate and sensitive way to identify lymph tumors is only 60 to 70%. The patients who relapse after node metastases. complete resection

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Feb 1, 2009

There are no references for this article.